The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
R | Respiratory system | |
2
|
R06 | Antihistamines for systemic use | |
3
|
R06A | Antihistamines for systemic use | |
4
|
R06AX | Other antihistamines for systemic use | |
5
|
R06AX22 | Ebastine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 10 mg |
| Active Ingredient |
|---|
|
Ebastine has been shown to produce a rapid and long-lasting inhibition of histamine-induced effect and to have a strong affinity towards H1-receptors. |
| Document | Type | Information Source | |
|---|---|---|---|
| EBASTEL Film-coated tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| KESTINE Coated tablet | MPI, EU: SmPC | Web Search |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.